(561) 802-3060 info@mri-news.com

Paula Dear joins Metabolic Research Institute

Paula Dear, Clinical Operations Supervisor at Metabolic Research Institute Inc.

Paula Dear, Clinical Operations Supervisor

Paula Dear comes to Metabolic Research Institute Inc. as our new Clinical Operations Supervisor with over 20 years of Clinical Research experience. She has worked in all aspects of Clinical research from Private practice, the corporate sector and oncology research at Bethesda hospital. An excellent team leader who follows FDA/ICH and GCP regulations, Paula is passionate about research and truly loves what she does while maintaining high quality assurance and subject safety.

Welcome Paula!

Clinical Trials

Metabolic Research Institute in West Palm Beach clinical trials poster

Today, we have better approaches in treating diabetes & other endocrine disorders.

Why? Because people like you took part in a clinical research trial.

Ask if one is right for you.

We enroll adult volunteers in clinical research studies in the following areas:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Hypertension
  • High Cholesterol and/orTriglycerides
  • Kidney Disease (Nephropathy)
  • Peripheral Neuropathy
  • Weight loss

There is no cost to participate in these research studies, and health insurance is not required.

Qualified participants will receive all study related examinations, lab tests and study medications at no cost. You may also be reimbursed for your time and travel.

For more information , talk with your doctor, call (561) 802-3060 or visit: www.metabolic-institute.com

ABOUT METABOLIC RESEARCH INSTITUTE:

Clinical studies are an integral part of clinical research and are at the heart of all advances in modern medicine. Our mission at the Metabolic Research Institute is to provide our patients and sponsors with the highest quality of diabetes clinical research available in today’s medical professional environment. We are committed to delivering efficient and timely research data, while focusing on strict adherence to protocol guidelines.

Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.

 

Eczema Study | Lunch and Learn Event

MRI holds eczema (atopic dermatitis) lunch and learn event.


Our recent Eczema Study | Lunch and Learn event was a great success.  Dr. Thomas Ross, a local dermatologist with over 20 years of experience, shared with our attendees many new and interesting facts about Eczema (Atopic Dermatitis) including its underlying causes, diagnosis and the treatments currently available to ease the skin conditions related to the disease.

Metabolic Research Institute Inc. (“MRI”) is currently recruiting volunteers for a clinical research study evaluating the safety and effectiveness of an investigational topical cream for use by patients aged 12 – 70 who have been diagnosed with mild to moderate eczema (atopic dermatitis).  If you (or someone you know) has been diagnosed with eczema (atopic dermatitis) and is interested in learning more about this study, please call MRI (561) 802-3060 or visit: https://www.metabolic-institute.com/dermatitis/

Oral Insulin Capsule for Type2DM

Clinical Research News

New Clinical Advances: Insulin Delivery Type 2 Diabetes
ORMD 0801 – INVESTIGATIONAL ORAL INSULIN CAPSULE FOR T2DM

Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.

Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 340 million type 2 diabetics worldwide with an economic burden of close to half a trillion dollars annually.

Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.

Oramed’s investigational oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. (source: https://www.oramed.com/pipeline/ormd-0801-type-2/)

Metabolic Research Institute Inc. (“MRI”) in West Palm Beach, Florida is currently recruiting adult volunteers to participate in this study. For more information, please call Metabolic Research at (561) 802-3060 or visit our website: https://www.metabolic-institute.com/dm2study/

About Metabolic Research Institute Inc.

Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.

Metabolic Research Institute’s clinical trials are designed to add to medical knowledge related to the treatment and prevention of diseases or conditions, whether it’s diabetes, high blood pressure, heart disease, high cholesterol, or a variety of other health issues.

Endocrinology Update for the Primary Care Practitioner

Free CME Educational Credits Available

 

Endocrinology Update flyerThis symposium will explore new guidelines and provide updates in the management of diabetes, thyroid and other endocrinologic disorders, and will introduce practical approaches to providing optimal patient care in these areas.

Registration is free…reservations required
Saturday September 28, 2019  |   7:00 AM – 5:00 PM

The intended audience for this conference includes primary care physicians and related medical professionals who are seeking to increase their understanding of diabetes, thyroid disease and other endocrine disorders.

Seminar topics to be covered will include:
• Diabetes and CVD • Practical Approaches to Insulin Therapy • Diabetes Technology Update • Hashimoto’s Disease • Osteoporosis • Thyroid Nodules • Obesity Management • Hypogonadism

 

 

Sponsored by Palm Beach Diabetes & Endocrine Specialists, PA
For more information, or to register for this event, go to: https://www.pbdes.com/endocrinology-seminar-2019/

Colorado Law Caps Monthly Insulin Costs at $100 for Insured Patients

Coloriado Governor signs insulin pricing reform

May 23, 2019 at 10:11am

-Craig Idlebrook

Yesterday, Colorado governor Jared Polis signed into law a measure that will cap total monthly insurance co-pays for insulin at $100. All insurers in the state will have to comply with the new regulation by January 1st, 2020.

The measure caps out-of-pocket costs for a 30-day supply of insulin at $100 for Coloradans with insurance. However, it does not provide a similar cap for out-of-pocket insulin costs for those in the state who lack insurance, nor does it cap out-of-pocket costs for other diabetes supplies.

The legislation also requires the Colorado Department of Law to investigate insulin pricing practices by pharmaceutical companies, pharmacy-benefit managers (PBMs), and insurers, and generate a report that will be made available to the public by November 1st, 2020.

The legislation does not block insurers or PBMs from offering monthly insulin copay caps lower than $100. Such a carve-out may prove important in the future, as insurers and PBMs have been under intense political pressure to cap out-of-pocket insulin costs. Recently, Cigna and Express Scripts rolled out a program in which participating customers will pay no more than $25 for a 30-day insulin supply.

The legislation’s passage was cheered by diabetes and disability advocates, including the American Diabetes Association.

The Colorado BioScience Association, CVS Health, United HealthCare, and Pharmaceutical Research and Manufacturers of America (PhRMA) all opposed the legislation, according to a regional policy report. Reasons to impose the measure included that it has the potential to drive up insurance plan costs and that it is being administered by the Colorado Department of Law, rather than state insurance or health care policy regulators.

This appears to be the first state law aimed specifically at capping insulin out-of-pocket costs. Many other states are considering bills aimed at reducing the economic burden of the insulin pricing crisis, according to a Healthline report.

You can read the final text of the new law here.